The proposed renewal of the T32 postdoctoral training program (EB005583) preserves the past focus on the areas of biomaterials science and tissue engineering, and extends the thematic landscape to broader challenges in regenerative medicine, with emphasis on stem cell based technologies. In doing so, the proposed program will continue its successful aspects: interdisciplinary collaboration and mentorship, accessibility to advanced resources and expertise, well-defined co-mentorship formats, and active progress tracking. The renewal plan adds three new overarching aims: 1. Expand the scientific content and faculty/institutions to emphasize regenerative medicine therapies, with increased interdisciplinary collaboration among materials scientists, pharmaceutical scientists and biologists, including a new focus on stem cells and translational research. Only stem cells compliant with federal guidelines will be used in the projects supported by T32 funding. 2. Increase the participation of clinicians, among both faculty and trainees. 3. Broaden the mentoring landscape from a single region/institution model to a more diverse and vibrant community of mentors and trainees, giving trainees a better critical mass of resources and mentors. This program will strongly emphasize translational research in order to prepare trainees to meet the critical challenges of regenerative healthcare for our aging population. There are substantial barriers to the commercialization of stem cell based therapies because of the still emerging nature of the technology, the ethical debates surrounding its use, and the uncertain nature of the business model for individualized products. As an adjunct to the core research experience, trainees will become familiar with the basic concepts and processes of clinical research and of commercialization that create the ultimate societal benefit of research. Faculty based in four geographic clusters (New Jersey-Pennsylvania, Boston MA, Rochester MN, and Cleveland OH) will host and mentor a total of eight trainees each year in interdisciplinary research projects drawing upon the strengths of the faculty laboratories and institutions. Each trainee will have a group of two to three mentors who will bring complementary expertise to the intensive two-year research experience (one year for clinicians). Required and elective didactic elements will provide background in scientific topics such as stem cell biology and biodegradable polymers, and in translational science topics such as regulatory processes and clinical trials research. Electronic technologies for online instruction and research collaboration will be implemented to facilitate creation of a distributed training community. All participants will attend an annual one- week workshop at Rutgers.

Public Health Relevance

This NRSA postdoctoral training program will offer collaborative research experiences built on core disciplines of biomaterials science, cell biology and pharmaceutical science. A geographically dispersed training community of eight trainees and 15 faculty mentors will engage in translational research to develop regenerative therapies based on tissue engineering, stem cells and drug delivery approaches. Both face-to-face and electronic interactions will be employed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Institutional National Research Service Award (T32)
Project #
2T32EB005583-11A1
Application #
8268219
Study Section
Special Emphasis Panel (ZEB1-OSR-E (J2))
Program Officer
Baird, Richard A
Project Start
2000-09-01
Project End
2017-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$290,066
Indirect Cost
$30,924
Name
Rutgers University
Department
None
Type
Organized Research Units
DUNS #
001912864
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Petersen, Latrisha K; York, Adam W; Lewis, Daniel R et al. (2014) Amphiphilic nanoparticles repress macrophage atherogenesis: novel core/shell designs for scavenger receptor targeting and down-regulation. Mol Pharm 11:2815-24
Cui, Mingjie; Naczynski, Dominik J; Zevon, Margot et al. (2013) Multifunctional albumin nanoparticles as combination drug carriers for intra-tumoral chemotherapy. Adv Healthc Mater 2:1236-45
Bushman, Jared; Vaughan, Asa; Sheihet, Larisa et al. (2013) Functionalized nanospheres for targeted delivery of paclitaxel. J Control Release 171:315-21
Lewis, Daniel R; Kholodovych, Vladyslav; Tomasini, Michael D et al. (2013) In silico design of anti-atherogenic biomaterials. Biomaterials 34:7950-9
York, Adam W; Zablocki, Kyle R; Lewis, Daniel R et al. (2012) Kinetically assembled nanoparticles of bioactive macromolecules exhibit enhanced stability and cell-targeted biological efficacy. Adv Mater 24:733-9
Chiang, Chunyi; Karuri, Stella W; Kshatriya, Pradnya P et al. (2012) Surface derivatization strategy for combinatorial analysis of cell response to mixtures of protein domains. Langmuir 28:548-56
Hsia, Henry C; Nair, Mohan R; Mintz, R Candida et al. (2011) The fiber diameter of synthetic bioresorbable extracellular matrix influences human fibroblast morphology and fibronectin matrix assembly. Plast Reconstr Surg 127:2312-20
Ghosh, Jayeeta; Lewitus, Dan Y; Chandra, Prafulla et al. (2011) Computational modeling of in vitro biological responses on polymethacrylate surfaces. Polymer (Guildf) 52:2650-2660
Joy, Abraham; Cohen, Daniel M; Luk, Arnold et al. (2011) Control of surface chemistry, substrate stiffness, and cell function in a novel terpolymer methacrylate library. Langmuir 27:1891-9
Lewis, Daniel R; Kamisoglu, Kubra; York, Adam W et al. (2011) Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3:400-20

Showing the most recent 10 out of 14 publications